{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-23-000131","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.354473+00:00","generated_at":"2026-06-08T07:14:57.998560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Immunovant reports Q2 FY2024 net loss of $58.7M; Phase 1 data supports IMVT-1402 best-in-class potential","bullets":["Net loss of $58.7M ($0.45/share) for Sep Q, vs. $47.9M ($0.41) a year ago; wider loss on higher R&D.","Initial Phase 1 data for IMVT-1402 showed dose-dependent IgG reductions without significant albumin or LDL changes.","Raised ~$467M net in October 2023 public/private offering; pro forma cash $737M as of Sep 30.","Expects initial 600mg MAD cohort data for IMVT-1402 in Nov 2023; Phase 2 Graves' data by year-end 2023.","Phase 3 MG top-line data expected H2 2024; TED data H1 2025; CIDP Phase 2b data H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-23-000131","json":"https://secwatch.observer/filing/0001764013-23-000131.json","markdown":"https://secwatch.observer/filing/0001764013-23-000131.md","text":"https://secwatch.observer/filing/0001764013-23-000131.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/0001764013-23-000131-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/imvt-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:14:57.998560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f86e53ec22f70e78bb3a309c5897a9be66996a92","claim":"Immunovant, Inc. reported financial results for fiscal second quarter and six months ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1764013/000176401323000131/0001764013-23-000131-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter and six months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}